ClinicalTrials.gg

Program

Alpelisib

Also written as “BYL719”, “alpelisib” and “BYL719 as film-coated (FC) whole tablets”.

Its studies are mostly in Breast Neoplasms · Squamous Cell Carcinoma of Head and Neck · Neoplasms · Ovarian Neoplasms · Lymphatic Abnormalities, led by 4 companies.

Furthest: phase 4, since Nov 21, 202237 company-led studies, 11 open or runningNext primary completion: Jan 28, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis3310 open or runningphase 4since Nov 21, 2022Oct 6, 2010Jan 28, 2027phase 3 · NCT05038735
Pfizer20 open or runningphase 2since Oct 30, 2012Oct 6, 2011none ahead
Criterium11 open or runningphase 2since Dec 27, 2021Dec 27, 2021none ahead
Kura Oncology10 open or runningphase 2since Jul 27, 2021Jul 27, 2021none ahead

Also a collaborator on its studies: ImmunityBio.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 24 studies since Oct 6, 2010.

  1. Aug 19, 2020Phase 2 study in Advanced Breast CancerNovartis · NCT04524000 · 24 enrolled · Japan
  2. Sep 3, 2020Phase 2 study in Breast NeoplasmsNovartis · NCT04544189 · 69 enrolled · China
  3. Oct 14, 2020Phase 2 study in PIK3CA-related Overgrowth Spectrum (PROS)Novartis · NCT04589650 · 236 enrolled · United States, Canada, China and more
  4. Jan 25, 2021Phase 3 study in Ovarian NeoplasmsNovartis · NCT04729387 · 358 enrolled · United States, Argentina, Australia and more
  5. Apr 21, 2021Phase 2 study in Advanced Breast CancerNovartis · NCT04862143 · 2 enrolled · Sweden
  6. Jul 19, 2021Phase 2 study in PIK3CA-related Overgrowth Spectrum (PROS)Novartis · NCT04980833 · 41 enrolled · United States, France, Ireland and more
  7. Jul 27, 2021Kura Oncology's first study: phase 2 study in Squamous Cell Carcinoma of Head and NeckNew to Kura OncologyKura Oncology · NCT04997902 · 45 enrolled · United States
  8. Sep 1, 2021Phase 3 study in Breast NeoplasmsNovartis · NCT05038735 · 210 enrolled · Belgium, Bulgaria, Canada and more
  9. Dec 27, 2021Criterium's first study: phase 2 study in HER2-positive Metastatic Breast CancerNew to CriteriumCriterium · NCT05230810 · 40 enrolled · United States
  10. Nov 21, 2022Phase 4 study in Multiple Endocrine Neoplasia Type 1Novartis · NCT05631795 · 40 enrolled · India
  11. Jul 4, 2023Phase 3 study in Lymphatic AbnormalitiesNovartis · NCT05948943 · 232 planned · United States, Argentina, Australia and more
  12. May 21, 2025Phase 2 study in PIK3CA-related Overgrowth Spectrum (PROS)Novartis · NCT06997588 · 140 planned · United States, Australia, Austria and more
  13. Jun 25, 2026Phase 2 study in Breast NeoplasmsNovartis · NCT07679269 · 51 planned
  14. Oct 5, 2026Primary completion moved from 2028-08-02 to 2029-01-29Date moved laterphase 2 · +6 months · NCT06997588

Ahead

  1. Jan 28, 2027Primary completion: phase 3 study in Breast NeoplasmsNovartis · NCT05038735
  2. Jan 29, 2027Primary completion: phase 2 study in Breast NeoplasmsNovartis · NCT04544189
  3. Feb 26, 2027Primary completion: phase 2 study in Advanced Breast CancerNovartis · NCT04524000
  4. Feb 26, 2027Primary completion: phase 3 study in Advanced HER2+Breast CancerNovartis · NCT04208178

TargetBeta

PIK3CA →read by rule
“PI3-kinase p110-alpha subunit inhibitor”ChEMBL 37, by rule

Other programs on PIK3CA

ProgramCompanyFurthest phaseStudies
inavolisibruleHoffmann-La Rochephase 320
tersolisibEli Lillyphase 310
gedatolisibrulePfizerphase 39
PI3K-alpha Inhibitor JS105rulerisen-suzhou-pharma-tech-co-ltdphase 31
serabelisibruleTakedaphase 211
paxalisibrulekazia-therapeutics-limitedphase 24
risovalisibruleHaihe Biopharmaphase 24
zovegalisibrulerelay-therapeutics-incphase 22
Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818rulepikavation-therapeutics-incphase 21
Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636ruleensem-therapeuticsphase 21
RAS/PI3K-alpha Inhibitor VVD-159642ruleBayerphase 11
PI3Ka H1047R Mutant Selective Inhibitor CGT6297rulecogent-biosciences-incphase 11

Studies

All 37 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07679269Breast Neoplasms2Not yet recruitingNovartisMar 23, 203251
NCT06997588PIK3CA-related Overgrowth Spectrum (PROS) · United States, Australia, Austria and more2RecruitingNovartisJan 29, 2029140
NCT05948943Lymphatic Abnormalities · United States, Argentina, Australia and more3RecruitingNovartisMay 31, 2028232
NCT05631795Multiple Endocrine Neoplasia Type 1 · India4CompletedNovartisJun 12, 202540
NCT05230810HER2-positive Metastatic Breast Cancer · United States2Active, not recruitingCriteriumMar 30, 202640
NCT05038735Breast Neoplasms · Belgium, Bulgaria, Canada and more3Active, not recruitingNovartisJan 28, 2027210
NCT04997902Squamous Cell Carcinoma of Head and Neck · United States2CompletedKura OncologyAug 29, 202545
NCT04980833PIK3CA-related Overgrowth Spectrum (PROS) · United States, France, Ireland and more2Active, not recruitingNovartisJun 22, 202741
NCT04862143Advanced Breast Cancer · Sweden2TerminatedNovartisSep 19, 20222
NCT04729387Ovarian Neoplasms · United States, Argentina, Australia and more3TerminatedNovartisApr 21, 2023358
NCT04589650PIK3CA-related Overgrowth Spectrum (PROS) · United States, Canada, China and more2Active, not recruitingNovartisMar 20, 2024236
NCT04544189Breast Neoplasms · China2Active, not recruitingNovartisJan 29, 202769
NCT04524000Advanced Breast Cancer · Japan2Active, not recruitingNovartisFeb 26, 202724
NCT04251533Triple Negative Breast Neoplasms · United States, Argentina, Australia and more3TerminatedNovartisMay 31, 2023137
NCT04208178Advanced HER2+Breast Cancer · United States, Belgium, China and more3Active, not recruitingNovartisFeb 26, 202719
NCT03439046Breast Neoplasms · Italy3TerminatedNovartisDec 11, 2023287
NCT03056755Breast Neoplasms · United States, Argentina, Belgium and more2CompletedNovartisJun 14, 2021383
NCT02624557Hepatic Impairment · United States1CompletedNovartisOct 1, 201723
NCT02437318Breast Neoplasms · United States, Argentina, Australia and more3CompletedNovartisJun 12, 2018572
NCT02276027Adenocarcinoma of Lung · China2CompletedNovartisOct 15, 201966
NCT02144038Recurrence · United States, Australia, Germany and more1CompletedNovartisOct 28, 201520
NCT02088684Breast Neoplasms · United States, France, Italy and more1CompletedNovartisApr 17, 201870
NCT02077933Neoplasms · United States, France, Germany and more1CompletedNovartisApr 12, 201979
NCT02051751Neoplasms · United States, France, Italy and more1CompletedNovartisAug 19, 201619
NCT02058381Pre-menopausal Breast Cancer · Hong Kong, Korea, Republic of, Taiwan and more1CompletedNovartisJun 19, 201840
NCT01928459Breast Neoplasms · United States, Australia, Belgium and more1CompletedNovartisAug 201662
NCT01923168Breast Neoplasms · United States, Australia, Austria and more2CompletedNovartisJul 7, 2017340
NCT01872260Breast Neoplasms · United States, Australia, France and more2Active, not recruitingNovartisFeb 26, 2027259
NCT01822613Esophageal Squamous Cell Carcinoma · United States, Belgium, Canada and more1CompletedNovartisJun 3, 201648
NCT017359683rd Line GIST · United States, Belgium, France and more1CompletedNovartisOct 19, 201856
NCT01719380Colorectal Neoplasms · United States, Australia, Belgium and more2CompletedPfizerOct 31, 2015156
NCT01708161Breast Neoplasms · United States, Belgium, Canada and more2TerminatedNovartisDec 26, 201447
NCT01613950Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein · United States, Germany, Japan and more1CompletedNovartisMar 201418
NCT01602315Squamous Cell Carcinoma of Head and Neck · United States, Australia, Canada and more2TerminatedNovartisSep 16, 2016179
NCT01449058Advanced and Selected Solid Tumors · United States, Australia, France and more1CompletedPfizerAug 31, 2016139
NCT01387321Advanced Solid Tumor · Japan1CompletedNovartisNov 25, 201533
NCT01219699Advanced Solid Tumors With an Alteration of the PIK3CA Gene · United States, Germany, Netherlands and more1CompletedNovartisFeb 5, 2015221

How it is read

Names in the registry

  • “Alpelisib”, 18 entries
  • “BYL719”, 13 entries
  • “alpelisib”, 3 entries
  • “BYL719 as film-coated (FC) whole tablets”, 1 entry
  • “BYL719 as dispersible tablets (DT)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.